Martingale Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Martingale Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$496K	Buy	38,653 +1,700	+5%	+$21.7K	0.01%	639
2025 Q4	$332K	Sell	36,953 -5,663	-13%	-$78K	0.01%	675
2025 Q3	$736K	Sell	42,616 -1,505	-3%	-$18.5K	0.02%	550
2025 Q2	$414K	Buy	44,121 +14,322	+48%	+$118K	0.01%	645
2025 Q1	$212K	Buy	29,799 +8,400	+39%	+$84.8K	0.01%	734
2024 Q4	$250K	Buy	+21,399	New	+$334K	0.01%	715
2018 Q2	–	Sell	-31,717	Closed	-$669K	–	1006
2018 Q1	$669K	Sell	31,717 -300	-0.9%	-$7.38K	0.01%	794
2017 Q4	$616K	Sell	32,017 -290	-0.9%	-$6.7K	0.01%	790
2017 Q3	$803K	Buy	+32,307	New	+$609K	0.01%	776

Other funds holding NTLA

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments

Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return